Percentage of telehealth visits was higher for mental health than other clinicians. HealthDay News — In 2021, 9.6% of medical visits took place via telehealth, with a higher percentage seen for mental ...

After a median follow-up of approximately 35.2 months, the median OS was 23.7 months for nivolumab plus ipilimumab vs 20.6 months for lenvatinib or sorafenib. Nivolumab in combination with ipilimumab ...

The availability of these generics is still unclear as the patent for Entresto does not expire until July 15, 2025. The Food and Drug Administration (FDA) has approved the first generics of Entresto ® ...

The program automatically reduces the cost of the inhaler at the pharmacy for eligible patients with commercial insurance. Out-of-pocket costs for Boehringer Ingelheim asthma and chronic obstructive ...

Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain. The Food and Drug Administration (FDA) has expanded the ...

Authors found that BMI of 27 or greater shows excellent diagnostic performance. HealthDay News — The optimal body mass index (BMI) cutoff point appears to be 27kg/m 2 for detecting obesity in ...

Greater use of weight management treatments seen with WNP, including bariatric surgery, low-calorie meal replacement. HealthDay News — A primary care-based weight navigation program (WNP) is feasible ...

Findings showed patients treated with plozasiran 25mg and 50mg had median triglyceride reductions of -80% and -78%, respectively, compared with -17% for placebo. Plozasiran significantly reduced ...

Results showed 30.4% of patients treated with mitapivat achieved a transfusion reduction response vs 12.6% of patients who received placebo. Mitapivat was associated with a significant reduction in ...

Credit: Moderna. The approval was based on data from the phase 3 ConquerRSV trial, which included approximately 37,000 adults 60 years of age and older. The Food and Drug Administration (FDA) has ...

Insmed plans to file a New Drug Application with the Food and Drug Administration in the fourth quarter of 2024. Treatment with brensocatib reduced the frequency of pulmonary exacerbations in ...